Bristol backs out of BET inhibition
A pipeline cull sees the US pharma joining AbbVie's exit, in the wake of Novartis’s big bet.
A pipeline cull sees the US pharma joining AbbVie's exit, in the wake of Novartis’s big bet.
The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.
After two years Loqtorzi is on the US market at last, and Coherus looks to its Surface acquisition to play the combo game.
Adding a kinase inhibitor to PD-L1 plus chemo could make a real difference in first-line SCLC, a little-appreciated Chinese trial suggests.
Mirati raises $300m as its chief exec departs. What’s not to like?